Introduction

There are not data on blood B-cell lymphoma 2 (Bcl-2) concentrations (one of the antiapoptotic molecules of the Bcl-2 family in the intrinsic apoptosis pathway) in septic patients. Therefore, this study was carried with the aims to explore whether blood Bcl-2 concentrations at diagnosis of sepsis are different in survivor and non-survivor septic patients, are associated with mortality, and are useful for the mortality prediction.

Methods

Intensive Care Units from 3 Spanish hospitals participated in this observational and prospective study with septic patients and serum Bcl-2 concentrations at diagnosis of sepsis were determined. Mortality at 30 days was as outcome variable.

Results

We found that 30-day non-surviving patients (n = 81) showed lower serum Bcl-2 levels (p = 0.003) than surviving patients (n = 140). We found that serum concentrations of Bcl-2 < 4.4 ng/mL were associated with mortality (OR = 3.228; 95% CI = 1.406–7.415; p = 0.006) in the multiple logistic regression analysis, and that showed an area under the curve for mortality prediction of 62% (95% CI = 55–68%; p = 0.003).

Conclusions

In our study appears novel findings such as higher blood Bcl-2 concentrations in survivor than in non-survivor septic patients, the association between low blood Bcl-2 concentrations and mortality of septic patients, and the ability of blood Bcl-2 concentrations for the prediction of septic patient mortality.

中文翻译：

---

循环 Bcl-2 浓度和脓毒症患者死亡率

介绍

没有关于脓毒症患者血液 B 细胞淋巴瘤 2 (Bcl-2) 浓度（内在细胞凋亡途径中 Bcl-2 家族的抗细胞凋亡分子之一）的数据。因此，本研究旨在探讨脓毒症诊断时的血液 Bcl-2 浓度在幸存者和非幸存者脓毒症患者中是否不同，是否与死亡率相关，以及是否有助于死亡率预测。

方法

来自 3 家西班牙医院的重症监护病房参与了这项针对脓毒症患者的观察性和前瞻性研究，并确定了脓毒症诊断时的血清 Bcl-2 浓度。30 天时的死亡率作为结果变量。

结果

我们发现 30 天未存活患者 ( n  =  81) 的血清 Bcl-2 水平 ( p  =  0.003) 低于存活患者 ( n  =  140)。我们发现，在多元逻辑回归分析中，Bcl-2  <  4.4  ng/mL 的血清浓度与死亡率相关（OR  =  3.228；95% CI  =  1.406–7.415；p  =  0.006），并显示曲线下面积死亡率预测为 62%（95% CI  =  55–68%；p  =  0.003）。

结论

在我们的研究中出现了新的发现，例如幸存者的血液 Bcl-2 浓度高于非幸存者的脓毒症患者，低血 Bcl-2 浓度与脓毒症患者死亡率之间的关联，以及血液 Bcl-2 浓度对脓毒症患者的能力脓毒症患者死亡率的预测。